Insights+: Key Events of ASCO 2019
Key Events of ASCO 2019
The American Society of Clinical Oncology (ASCO) is a platform for cancer experts to share views on latest advancement and new approaches in cancer research. In the 55th session of ASCO 2019, 2400+ abstracts were presented. IBM Watson Health was also a part of ASCO 2019 with its advancement in Oncology, Genomics and Patient Monitoring. The top Pharma companies like Roche, Merck has presented their data. Our team at PharmaShots has summarized and complied the key events of ASCO 2019.
Date- May 31, 2019
Products- Erleada, Apalutamide
The P-III TITAN study involves assessing of Erleada + Androgen Deprivation Therapy (ADT) vs PBO + ADT in 1050 patients in ratio 1:1 with mCSPC across 23 countries.The P-III study results: @22.7 mos. OS (82% vs 74%); PSA (68% vs 29%); 52% reduction in risk of radiographic progression; 61% reduction in time to cytotoxic CT; 34% reduction in PFS2. Erleada (apalutamide) is an androgen receptor (AR) inhibitor and has received FDA approval for patients with non-metastatic castration-resistant prostate cancer (nmCRPC) on 14 Feb,2018. The results of P-III TITAN study will accelerate the approval of Erleada for mCSPC.
Date- Jun 3, 2019
Products- Lynparza, Olaparib
The P-III POLO study involves assessing of Lynparza (olaparib, 300mg, bid) vs PBO in 154 patients in ratio (3:2) with BRCAm metastatic pancreatic cancer whose disease had not progressed on 1st-line Pt-based CT. The P-III POLO study results: improvement in PFS (7.4 vs 3.8 mos.); @1yr & 2yrs. no disease progression (34% & 22% vs 15% & 10%) respectively. Lynparza (olaparib) is a PARP inhibitor targeted for DNA damage response (DDR) pathway deficiencies, including BRCA mutations. In 2017, Merck and AstraZeneca collaborated to co-develop and co-commercialize Lynparza globally.
3. IBM Watson Health Reports Real-World Progress of AI in Oncology in #ASCO2019
Date- May 30, 2019
Products- Oncology
IBM Watson has presented 22 new scientific studies showing progress in clinical studies of cancer using AI-Technology with informed decisions based on curated scientific evidences, insights and information which are unidentified manually and further leading to QoL .The presented data includes: Watson For Oncology lead to 13.6% changes in informs clinical decision reviewed by multidisciplinary tumor board; Watson For Genomics Surfaces resulted in new insights for oncologists to treat hematological malignancies; Watson For Oncology improves cancer patient confidence. Additionally, IBM Watson reported to identify automatically, high-quality and relevant scientific publications with the help of machine learning on words from abstracts of papers cited at three expert resources: NCCN, NCI-PDQ, and Hemonc.org further resulting in 93% accuracy, 95% sensitivity, and 91% specificity of treatment
Date- Jun 3, 2019
Products- Enfortumab Vedotin
The P-II EV-201 study involves assessing of Enfortumab Vedotin in patients with locally advanced or metastatic urothelial cancer who have been previously treated with a PD-1/L1 inhibitor including those who have also been treated with Pt-CT. P-II EV-201 results: ORR 44%; DOR 7.6 mos.; mOS 11.7 mos.; mPFS 5.8 mos.; CR 12%; presented at ASCO 2019. Enfortumab vedotin is an investigational ADC candidate targeting Nectin-4 protein, currently evaluated in P-III EV-301 study for LA or metastatic urothelial cancer. In 2007, Seattle and Astellas entered a co-development deal for enfortumab vedotin, plans to submit BLA to FDA based on EV-201 results
Date- Jun 3, 2019
Products- Lynparza, olaparib
The P-III SOLO3 study results involves assessing of Lynparza (300mg, bid) vs CT (paclitaxel/topotecan /pegylated liposomal doxorubicin/gemcitabine) in 266 patients in a ratio (2:1) with 2L+ platinum-sensitive relapsed BRCA1/2-mutated (gBRCAm) advanced ovarian cancer. The P-III SOLO3 study results: improvement in ORR (72.2% vs 51.4%); PFS (13.4 mos. vs 9.2mos.); safe & tolerable, presented at ASCO 2019. Lynparza is a PARP inhibitor, targeted for DNA damage response (DDR) pathway deficiencies, including BRCA mutations and has received approval in 64 & 38 countries as a maintenance treatment of platinum-sensitive relapsed ovarian cancer & 1L gBRCAm HER2- metastatic breast cancer respectively.
Date- Jun 3, 2019
Products- Kisqali, Ribociclib
The P-III MONALEESA-7 study results involves assessing of Kisqali in combination with endocrine therapy (goserelin + aromatase inhibitor/tamoxifen) vs endocrine therapy as monothx. in pre- and perimenopausal women with HR+/HER2- advanced or metastatic breast cancer. The P-III MONALEESA-7 study resulted in improving survival rate @42mos. (70.2% vs 46.0%), 30%/20.9% reduction in risk of death, no new safety signals were observed, presented at ASCO 2019 respectively. Kisqali is the CDK4/6 inhibitor, currently evaluated in P-III NATALEE study with endocrine therapy as an adjuvant treatment of HR+/HER2- early breast cancer and is approved in 75+ countries including the US & EU for the same indication.
Date- Jun 3, 2019
Products- Isatuximab
The P-III ICARIA-MM study results involve assessing of Isatuximab (10mg/kg, qw) + pomalidomide and dexamethasone (pom-dex) vs pom-dex in 307 patients with r/r multiple myeloma across 24 countries. The P-III ICARIA-MM study result: improvement in m-PFS (11.53mos. vs 6.47 mos.); ORR (60% vs 35%); VGPR rate (31.8% vs 8.5%); DOR (13.27mos. vs 11.07mos); median time to first response (35 days vs 58 days), presented at ASCO 2019 in Chicago. Isatuximab is a mAb targeting specific epitope on the CD38 receptor, designed to promote apoptosis & immunomodulatory activity, currently being evaluated in multiple P-III studies for multiple myeloma. EMA has accepted its MAA in Q2’19 and Sanofi has also filed FDA’s BLA for RRMM.
Date- Jun 4, 2019
Products- PB272, Neratinib, Capecitabine, Tykerb, Lapatinib
The P-III NALA trial involves assessing of neratinib + capecitabine vs Tykerb (lapatinib) + capecitabine in 621 patients in ratio (1:1) with 3L HER2-positive metastatic breast cancer. P-III NALA Trial results: mPFS (8.8 mos. vs 6.6 mos.); mOS (21.0 mos. vs 18.7 mos.); mean OS @48 mos. (24.0 mos. vs 22.2 mos.); overall cumulative incidence of CNS metastases (22.8% vs 29.2%); DOR (8.54 mos. vs 5.55 mos.); TEAEs (10.9% vs 14.5%). PB272 is a tyrosine kinase inhibitor and its oral formulation has received the US FDA’s approval for the extended adjuvant treatment in adults with early stage HER2-overexpressed/amplified breast cancer in Jul’17, marketed as Nerlynx (neratinib) tablets in the US.
Date- Jun 4, 2019
Products- Venclexta/Venclyxto, Venetoclax, Gazyva/Gazyvar
The P-III CLL14 Study involves assessing of Venclexta/Venclyxto + Gazyva/Gazyvar vs Gazyva/Gazyvaro + chlorambucil in 432 patients with previously untreated chronic lymphocytic leukemia (CLL). P-III CLL14 Study results: ORR (84.7% vs 71.3%); CR (49.5% vs 23.1%); patients receiving Venclexta/Venclyxto lived longer; disease progression @2yrs. (88.2% vs 64.1%); no new safety signals observed. Venclexta/Venclyxto is a drug targeted for binding & inhibiting BCL-2 protein, further leads to apoptosis and has received 5 times FDA’s BT designation in combination or monothx with approval in 50+ countries. Roche and AbbVie collaborated to develop Venclexta/Venclyxto.
Date- Jun 4, 2019
Products- Capmatinib
The P-II GEOMETRY mono-1 study results involves assessing of Capmatinib (400mg, bid) in 97 treatment-naive & prior treated patients with LA/metastatic NSCLC harboring a MET exon-14 skipping mutation. The P-II GEOMETRY mono-1 study results: ORR based on BIRC assessment / RECIST v1.1 (68% & 41%); DOR (11.14 mos. & 9.72 mos.), 54% patients showed intracranial activity, presented at ASCO 2019. Capmatinib (INC280) is an oral & selective MET inhibitor, licensed by Novartis from Incyte Corporation in 2009 and has received FDA’s BT designation for m-NSCLC with MET exon-14 skipping mutation. Additionally, Novartis presents data of canakinumab (ACZ885) as monothx. in P-III CANOPY study for mid- to late-stage NSCLC.
Note- This insight report is a compilation of ASCO2019 associated news published by PharmaShots in chronological order
Image Source: tgpadova